Article

Occidiofungin's chemical stability and in vitro potency against Candida species.

Department of Biological Sciences, Mississippi State University, Mississippi State, Mississippi, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 11/2011; 56(2):765-9. DOI:10.1128/AAC.05231-11
Source: PubMed

ABSTRACT Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans. MICs against Candida species were between 0.5 and 2.0 μg/ml. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum with a minimal lethal concentration (MLC) of 2 and 4 μg/ml, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin against Candida albicans were performed. The results demonstrate that occidiofungin is fungicidal. Occidiofungin was also found to be a very stable molecule. It is resistant to extreme temperatures and pH and maintains its activity following exposure to gastric proteases.

0 0
 · 
0 Bookmarks
 · 
153 Views
  • [show abstract] [hide abstract]
    ABSTRACT: Burkholderia contaminans strain MS14 produces the antifungal compound occidiofungin, which is responsible for significant antifungal activities against a broad range of plant and animal fungal pathogens. Occidiofungin is a cyclic glycolipopeptide made up of eight amino acids and one xylose. A 56-kb ocf gene cluster was determined to be essential for occidiofungin production. In this study the ocfC gene, which is located downstream of ocfD and upstream of ocfB gene in the ocf gene cluster, was examined. Antifungal activity of the ocfC gene mutant MS14KC1 was reduced against the indicator fungus Geotrichum candidum compared with the wild-type strain. Furthermore, the analysis of the protein sequence suggests that the ocfC gene encodes a glycosyltransferase. Biochemical analyses using NMR and Mass spectroscopy revealed that the ocfC mutant produced the occidiofungin without the xylose. Purified ocfC mutant MS14KC1 product had similar level of bioactivity as compared to the wild-type product. The revertant MS14KC1-R of the ocfC mutant produced the same antifungal activity level on plate assays and the same antifungal compound based on HPLC and mass spectroscopy analysis as the wild type strain MS14. Collectively, the study demonstrates the ocfC gene encodes a glycosyltransferase responsible to add a xylose to the occidiofungin molecule and that the presence of the xylose is not important for antifungal activity against Candida species. The finding provides a novel variant for future studies aimed at evaluating its use for inhibiting clinical and agricultural fungi and the finding could also simplify the chemical synthesis of occidiofungin variants.
    Applied and environmental microbiology 02/2013; · 3.69 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Members of the Burkholderia cepacia complex (Bcc) have recently gained notoriety as significant bacterial pathogens due to their extreme levels of antibiotic resistance, their transmissibility in clinics, their persistence in bacteriostatic solutions, and their intracellular survival capabilities. As pathogens, the Bcc are known to elaborate a number of virulence factors including proteases, lipases and other exoproducts, as well as a number of secretion system associated effectors. Through random and directed mutagenesis studies, we have identified a Bcc gene cluster capable of expressing a toxin that is both hemolytic and required for full Bcc virulence. The Bcc toxin is synthesized via a non-ribosomal peptide synthetase mechanism, and appears to be related to the previously identified antifungal compound burkholdine or occidiofungin. Further testing shows mutations to this gene cluster cause a significant reduction in both hemolysis and Galleria mellonella mortality. Mutation to a glycosyltransferase gene putatively responsible for a structural-functional toxin variant causes only partial reduction in hemolysis. Molecular screening identifies the Bcc species containing this gene cluster, of which several strains produce hemolytic activity.
    Virulence 05/2012; 3(3):286-98. · 2.79 Impact Factor

Full-text (2 Sources)

View
14 Downloads
Available from
Aug 19, 2013